PDE10A and schizophrenia: Therefore, controlling their activity in the CNS could potentially be beneficial towards neurodegenerative and neuropsychiatric conditions such as Alzheimer's and Parkinson's disease.[87, 88] Hu and co‐workers[22] tried to identify PDE10A inhibitors, as its inhibition could present a novel target for the treatment of schizophrenia.[87] This enzyme is highly expressed in brain tissue, especially in the striatum, thought to be disregulated in schizophrenia and an antagonist may have therapeutic benefit.